ライフサイエンスコーパス: thrombose

1 els), and 1.9% were in class IV (all vessels thrombosed).

2 the enlarged vein, causing the hemorrhoid to thrombose.

3 ability to inhibit both venous and arterial thromboses.

4 ved to influence the development of arterial thromboses.

5 ology of rejection characterized by vascular thromboses.

6 elet reactivity with a resulting increase in thromboses.

7 ther conditions associated with pathological thromboses.

8 rovascular aneurysms, or arterial and venous thromboses.

9 atment with heparin resulting in paradoxical thromboses.

10 the cost of an increased risk of late stent thromboses.

11 s of heart disease are at increased risk for thromboses.

12 ents with rapidly progressive multiple organ thromboses.

13 body blood vessels in the treated area were thrombosed 1 day after PDT.

14 urred in 8 pts (23.5%): 4 bleeding, 3 portal thromboses (1 complete, 2 partial), and 1 sepsis.

15 the fish oil group, there were half as many thromboses (1.71 vs 3.41 per 1000 access-days; IRR, 0.50

16 perior in the prevention of catheter-related thromboses (13 [3%] vs 34 [7%]; 0.38, 0.20-0.71, p=0.002

17 tenoses, one dissection), 185 in the EIA (17 thromboses, 167 stenoses, one dissection), one in the co

18 ases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial and venous thrombosis, 2

19 did not reduce the rate of catheter-related thromboses (24 [6%] vs 24 [6%]; relative risk 0.99, 95%

20 FvQ/Q mice formed occlusive thromboses 27+/-3 minutes (n=7) after the onset of injur

21 ke (2.44 [1.04-5.75], p = 0.04) and arterial thromboses (3.49 [0.97-12.54], p = 0.05).

22 was compromised in 20 cases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial a

23 pulmonary embolisms (42.2%), and deep venous thromboses (34.5%).

24 A clinically significant HAC (4 thromboses, 35 HACs requiring IVI) was found in 2.9% (n

25 imultaneous patients had more renal vascular thromboses (4.4% vs 1.3% tx alone, 0% pre; P = 0.04).

26 intimal dissections, 11 pseudoaneurysms, 17 thromboses, 4 carotid cavernous fistulas, and 1 transect

27 A risk-benefit analysis found 3 fewer stent thromboses (95% CI: 2 to 5) and 6 fewer MIs (95% CI: 2 t

28 s and venules in the subcutaneous layer were thrombosed and the overlying tissue was infarcted.

29 ts to proximal pulmonary arterial aneurysms, thromboses and calcification; to truncal valve stenosis

30 ischemic stroke comprise the major arterial thromboses and deep-vein thrombosis and pulmonary emboli

31 r mediated pathways leading to microvascular thromboses and endothelial activation appear to play an

32 A combined endpoint of thromboses and major bleeding showed no difference betwe

33 ies are at risk for major abdominal vascular thromboses and organ infarction.

34 symptoms to life-threatening events such as thromboses and strokes.

35 a single injection of 1,000 units, initially thrombosed, and recurred.

36 7%) were non-catheter-associated deep venous thromboses, and 9 (0.6%) were pulmonary emboli.

37 ythropoiesis and granulopoiesis, more venous thromboses, and a higher rate of polycythaemic transform

38 Thromboses are a serious complication in patients with s

39 but catheter occlusions and catheter-related thromboses are common complications that can result from

40 treatment of central venus catheter-related thromboses are critical in the treatment of patients req

41 Thromboses are detected frequently around the time of on

42 Other thromboses are found on non-ruptured but inflamed plaque

43 Catheter-related thromboses are usually diagnosed by Doppler ultrasonogra

44 Gender differences in vascular thromboses are well known, and there is evidence that pl

45 Ten thrombosed arteries were randomly assigned to receive ea

46 thrombocytopenic purpura and other arterial thromboses associated with compromised VWF proteolysis.

47 Nine en bloc kidneys thrombosed at a mean of 4.2 days posttransplantation.

48 ring revision of TIPS with one to five prior thromboses at 1 day to 1 year after initial TIPS formati

49 nted with Fv+/+ bone marrow formed occlusive thromboses at 35+/-5 minutes (n=7, P<0.05 compared with

50 AMTS-13 activity, and VWF-rich microvascular thromboses at autopsy.

51 Five patients (33%) developed venous thromboses at the central catheter tip.

52 l external iliac arteries of 15 canines were thrombosed before mechanical thrombolysis.

53 We found distorted, degenerating, or thrombosed blood vessels within the center of more than

54 Vascular thromboses, bowel perforation, septicemia, and retranspl

55 he 20 pancreas grafts, 15 are functioning, 3 thrombosed, but 2 of those patients underwent immediate

56 prevent CVC infections and catheter-related thromboses, but confirmatory studies and cost-effectiven

57 es of the popliteal artery and the number of thrombosed calf veins was investigated.

58 Catheter-related thromboses can lead to catheter infection, pulmonary emb

59 he manipulation of a Swan Ganz catheter in a thrombosed central vein, resulted in pulmonary emboli th

60 and malapposed struts were more frequent in thrombosed compared with nonthrombosed regions (ratio of

61 axial malapposition distance, was greater in thrombosed compared with nonthrombosed segments.

62 inding in human VCA, consisting of capillary thromboses (CT) in the upper dermis.

63 An uncomplicated deep vein thromboses developed in one patient with a history of re

64 Thromboses developed in six of 240 flaps (2.5%): 4 were

65 e considered as an alternative treatment for thrombosed dialysis fistulas.

66 sis patients (8 males and 4 females) with 14 thrombosed distal forearm Brescia-Cimino radiocephalic f

67 mboli (PE) in cancer patients with deep vein thromboses (DVT) was reviewed to identify indications, p

68 The primary outcome was deep vein thromboses (DVTs) averted.

69 ncrease the risk that recently-placed stents thrombose, especially when surgery is performed early af

70 mia should undergo ultrasonography to detect thromboses even if the physical examination is normal.

71 to pharmacological triggering, plaques that thrombosed exhibited significantly higher CLIO-CyAm7 acc

72 p, leg thrombi were only 50% detectable, the thrombosed femoral area had relative counts of 118%+/-17

73 tectable, mean (+/-SD) relative count in the thrombosed femoral area was 186% (+/-30%) of the contral

74 only 75% detectable, relative counts in the thrombosed femoral areas decreased to 125% (+/-20%), and

75 chnical and clinical success was found in 12 thrombosed fistulas.

76 h late portal vein or vena caval stenoses or thromboses from a cohort of 524 grafts with survival gre

77 may permit salvage or timely removal of the thrombosed graft.

78 Thrombosed grafts were treated successfully in 1,123 of

79 Two patients with symptoms of in situ thromboses had a higher percentage of adherent cells com

80 imilarly successful in the recanalization of thrombosed hemodialysis access grafts and achieved compa

81 122 randomly chosen patients with synthetic, thrombosed hemodialysis access grafts from multiple cent

82 The PTD is safe and effective for treating thrombosed hemodialysis access grafts.

83 ld be adopted as the treatment of choice for thrombosed hemodialysis access grafts.

84 20 adult patients with recently (</=14 days) thrombosed hemodialysis grafts.

85 ocytopenia (HIT) develop clinically apparent thromboses (HITT) remains uncertain.

86 The main PV (MPV) was completely thrombosed in 17 of 44 (39%) patients; near complete (>9

87 among patients without thrombosis; among 40 thromboses in 40 patients who did not undergo transplant

88 and comparable between groups, with no stent thromboses in any group at 6 months.

89 rent CAPS characterized by multiple arterial thromboses in large and small vessels despite maximal an

90 ion in symptomatic catheter-related or other thromboses in patients with cancer and therefore we shou

91 population there were 22 (16.5%) episodes of thromboses in the fondaparinux group and 13 (21.4%) in t

92 om 6 months to 3 years there were more stent thromboses in the Taxus group (hazard ratio 0.19 [95% co

93 e confirmed in 66 patients; an additional 36 thromboses in unique devices were suspected.

94 Risk factors for catheter-related thromboses include previous catheter infections, malposi

95 Prevention of catheter-related thromboses includes proper positioning of the CVC and pr

96 ), pulmonary embolism (n = 32), other venous thromboses (including deep vein thrombosis) (n = 42), an

97 Twenty-two (52%) had major vascular thromboses, including those in the inferior vena cava (n

98 nt is difficult and the complications of the thrombosed IVC may compromise life.

99 .9-27.4 kg) with end-stage renal disease and thrombosed IVCs were reviewed.

100 The non-thrombosed lesion that most resembles the acute plaque r

101 necrotic core prolapse was more frequent in thrombosed lesions compared with patent lesions (70% vs.

102 Thromboses limited to infrapopliteal leg deep veins (iso

103 hemobilia due to the rupture of a partially thrombosed mycotic aneurysm into the biliary tree.

104 ocardial infarction (n = 34), other arterial thromboses (n = 26), pulmonary embolism (n = 32), other

105 mechanical thrombolysis for the treatment of thrombosed native arteriovenous fistula.

106 ble, and safe procedure for the treatment of thrombosed native arteriovenous fistula.

107 No deaths, malignancies, or thromboses occurred during the trial.

108 Stent thromboses occurred in 1 patient assigned to placebo <24

109 Two maternal valve thromboses occurred.

110 win sister, who was diagnosed with extensive thromboses of the inferior vena cava, portal vein, and h

111 vents per 100 patient-years) compared with 2 thromboses on eculizumab (0.8 events per 100 patient-yea

112 These studies demonstrate markedly increased thromboses on stents with blood isolated from HPA Tg mic

113 fold group had definite or probable scaffold thromboses (one definite acute, one definite sub-acute,

114 ntitia causing saccular aneurysms, which can thrombose or rupture.

115 neurysms may erroneously be considered to be thrombosed or be mistaken for other common lesions such

116 -risk groups such as those with prior venous thromboses or coexistent defects of anticoagulation and

117 32-65 years; mean age, 42 years), abdominal thromboses or ischemic events were detected at CT.

118 Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and conf

119 nhanced CT revealed no recanalization of the thrombosed PAVM.

120 In thrombosed plaques, nanoparticles accumulated preferenti

121 ithin 2 weeks of function), one child with a thrombosed polar artery had a focal defect.

122 MVT replaces the liver and the thrombosed portomesenteric system.

123 factors [HRF] (multiple arteriovenous access thromboses, prior deep vein thrombosis, prior allograft

124 Obstructive thrombosed prosthetic heart valve (OTPHV) is a serious c

125 In cases where a chronically thrombosed PV has become obliterated, we developed PV re

126 arotid arteries of ApoE(-/-), HPS3(+/+) mice thrombosed rapidly after FeCl(3) injury, but ApoE(-/-),

127 s risk factors in patients with a history of thromboses; red cell binding sites on endothelial cells

128 des fusiform and saccular aneurysms that can thrombose, SA/C vasculitis likely causes the transition

129 2 combined arterial and venous thrombosis, 2 thromboses secondary to allograft pancreatitis, and 3 ca

130 of gamma counts from the femoral area on the thrombosed side was compared with the contralateral side

131 cluded vessels required puncture through the thrombosed sites using a stiff wire or transseptal needl

132 In one patient, the partially thrombosed splenic artery was opened at the tail of the

133 tiple vessel-related complications including thromboses, stenoses, occlusions, and aneurysms.

134 tiple vessel-related complications including thromboses, stenoses, occlusions, and aneurysms.

135 There were no instances of graft vascular thromboses/stenoses/leaks (0%).

136 view of CT scans revealed more grade 1 and 2 thromboses than were initially reported.

137 atient with a history of recurrent deep vein thromboses that had no adverse effect on her outcome.

138 ght heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated.

139 hepatic artery stenoses, six hepatic artery thromboses, two hepatic artery pseudoaneurysms, two sple

140 , are biocompatible, and show intact, though thrombosed, vasculature.

141 The luminal diameter of thrombosed veins was equal to or larger than that of a c

142 ategies have been used to restore patency of thrombosed veins, including open surgical thrombectomy,

143 In patients with 1 and/or 2 thrombosed veins, the mean PI was 6.03+/-0.54 on the sid

144 Inpatients with 3 and/or 4 thrombosed veins, the mean PI was 8.05+/-0.61 on the sid

145 ombus thickness was significantly greater in thrombosed versus patent lesions.

146 Those patients with multiple thrombosed vessels (class III and above) should be stron

147 ucer may be a method of recanalizing acutely thrombosed vessels if the impulses are applied only when

148 lts, 51.9% of patients fell into class I (no thrombosed vessels), 21.7% were in class II (one occlude

149 rombosis), 24.5% were in class III (multiple thrombosed vessels), and 1.9% were in class IV (all vess

150 with synthetic forearm loop shunts that were thrombosed were randomly assigned to undergo pharmacomec

151 Stent thromboses were also assessed.

152 A total of 72 pump thromboses were confirmed in 66 patients; an additional

153 Main sites of thromboses were deep veins of the extremities (10 of 23;

154 uary 2008 and September 2013, 26 (0.61%) THV thromboses were reported out of 4266 patients undergoing

155 No late stent thromboses were seen in any treated group despite clopid

156 passing treatment of any unknown concomitant thromboses with only low risk for hemorrhage.

157 symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen.

158 There were no deep vein thromboses, with 1 superfificial venous thrombosis in ea